1. Home
  2. LBRDK vs DNTH Comparison

LBRDK vs DNTH Comparison

Compare LBRDK & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LBRDK

Liberty Broadband Corporation Class C

HOLD

Current Price

$30.78

Market Cap

4.8B

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$99.86

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRDK
DNTH
Founded
2014
2015
Country
United States
United States
Employees
1900
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
LBRDK
DNTH
Price
$30.78
$99.86
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$121.00
AVG Volume (30 Days)
1.7M
1.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,036,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$109.28
$29.48
P/E Ratio
$10.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.08
$18.08
52 Week High
$91.79
$102.37

Technical Indicators

Market Signals
Indicator
LBRDK
DNTH
Relative Strength Index (RSI) 43.44 61.44
Support Level $29.37 $79.27
Resistance Level $34.95 N/A
Average True Range (ATR) 1.76 5.39
MACD 0.04 0.67
Stochastic Oscillator 7.81 82.57

Price Performance

Historical Comparison
LBRDK
DNTH

About LBRDK Liberty Broadband Corporation Class C

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: